BioGemex

NEWS & EVENTS

NEWS & EVENTS

Subject

Notice: March, 2020 "XDX-01 mentioned at point-of-care diagnostics market report"…

Name BioGemex
Date 20-03-19 15:02
View 110회

Contents

March, 2020 "XDX-01 mentioned at point-of-care diagnostics market report"


A report announced from "Grand View Research" at March, 2020 mentioned XDX-01 as one of the product insights.


Report title: "Point of Care Diagnostics Market Size, Share & Trends Analysis Report By Product (Glucose Testing, Blood Gas/ Electrolytes, Cancer Marker), By End Use (Clinics, Hospital), By Region, And Segment Forecasts, 2020 - 2027"


Report link: https://www.grandviewresearch.com/industry-analysis/point-of-care-poc-diagnostics-industry


Cited: The glucose testing segment accounted for the largest revenue share in 2019. One of the factors attributive for the larger share is a high prevalence of diabetes globally. As per data reported by the International Diabetes Federation, in 2019 around 463 million adults had diabetes globally and it is expected to reach 700 million cases in 2045. This raises the demand for point of care diagnostics or testing glucose meters that efficiently diagnose glycemic levels in diabetic patients and enhance disease management.

Growing popularity of wearable or portable glucose meters due to their speed, easy operation, and less cost is anticipated to drive the demand for glucose testing. Rise in potential applications of these devices further propels segment growth. For instance, glucose meters assist the determination of various targets by coupling of target recognition elements, such as nucleic acid hybridization, with signal transduction and amplification strategies. 

Emerging partnerships and collaborations among the key vendors support the point of care cancer diagnostics or testing. For instance, in August 2019, Xylonix along with BioGemex developed XDX-01, which is a pretreatment point of care diagnostics or testing method to detect the immunotherapy reactions in patients with solid tumors. Such innovations in cancer diagnosis are expected to drive the cancer marker segment at the fastest growth rate in the near future.


Ends
 

Media inquires 

BioGemex
Email: media@biogemex.com
Tel: +82-02-551-7700



Business

#303, World Trade Tower, 511, Yeongdong-daero, Gangnam-gu, Seoul, 06164, Korea

TEL : +82-2-551-7700

FAX : +82-2-551-7701

EMAIL : business@biogemex.com

R&D

#317, Hyundai I-Valley, 31, Galmachi-ro 244beon-gil, Jungwon-gu, Seongnam-si, Gyeonggi-do, 13212, Korea

TEL: +82-70-7753-2260

FAX : +82-31-737-9806

EMAIL: rnd@biogemex.com

Manufacture

#318, Hyundai I-Valley, 31, Galmachi-ro 244beon-gil, Jungwon-gu, Seongnam-si, Gyeonggi-do, 13212, Korea

TEL : +82-31-737-9800

FAX : +82-31-737-9806

EMAIL : manufacture@biogemex.com